Personalized medicine approach for novel microglia-associated genetic variants in Alzheimer's disease

Akronym

PMG-AD

Bidragets beskrivning

Alzheimer's disease (AD), the main cause of dementia world-wide, is clinically manifested as memory impairment and executive dysfunction. Most of the pathomechanistic studies in AD have so far largely concentrated on neurons, neglecting the role of other brain cells in neurodegeneration. The goal in the PMG-AD is to establish a personalized medicine-based approach for identification of early biomarkers and therapeutic targets in AD by focusing on novel AD-associated genetic variants in ABI3 and PLCG2 genes and consequently utilizing the latest research methodologies, human-based model systems and cohorts, and PET imaging, multilevel omics, integrative bioinformatic and endophenotype analyses to advance understanding of the role of microglia in AD. This new knowledge will advance the identification of novel candidates as personalized medicine-based biomarker and therapeutic targets for AD.
Visa mer

Startår

2020

Slutår

2023

Beviljade finansiering


Mikko Hiltunen Orcid -palvelun logo
148 572 €

Rollen i Finlands Akademis konsortium

Ledare

Övriga parter i konsortiet

Partner
Helsingfors universitet (334803)
148 272 €

Finansiär

Finlands Akademi

Typ av finansiering

Kansainvälinen yhteisrahoitteinen ohjelma

Övriga uppgifter

Finansieringsbeslutets nummer

334802

Vetenskapsområden

Neurovetenskaper

Forskningsområden

Neurotiede

Identifierade teman

brain, neuroscience